Bildkälla: Stockfoto

Alzinova: Interim Data From Phase Ib Study - Redeye

Redeye comments on the new positive safety review and interim data from the ongoing phase Ib study with vaccine candidate ALZ-101.

Redeye comments on the new positive safety review and interim data from the ongoing phase Ib study with vaccine candidate ALZ-101.
Börsvärldens nyhetsbrev
ANNONSER